TickerSparkInvestor Intelligence
TickerSparkInvestor Intelligence
Community
Main Feed
Today's Market Intel
Top Stocks
AI-Curated Stock Lists
IPO Calendar
Upcoming Listings
Stock Teasers
The Stock Behind the Promo
Trending Stocks
Today's Big Movers
Earnings Coverage
Flashes & Deep Dives
Macro Updates
Economy & Markets
Stock Reports
AI Research Reports
Commentary
Opinionated Stock Takes
Custom Reports
Stock Deep Dives · Free to Try
AI Analyst
Agentic Chat · Free to Try
Watchlist
Track Your Stocks · Free
Spark Charts
AI Technical Analysis · Free to Try
Intel Dashboard
Daily Trade Ideas
Trade Tracker
AI-Managed Portfolio · Pro
My Portfolio
Brokerage Connected · Pro
Custom Reports
Stock Deep Dives
AI Analyst
Agentic Chat
Watchlist
Your Stocks & Notes
Spark Charts
AI Technical Analysis
Intel Dashboard
Daily Trade Ideas
Trade Tracker
AI-Managed Portfolio
My Portfolio
Brokerage Connected
Account
Plan, Billing & Appearance
Log inCreate Account
← Back to TickerSpark
▌Research Report·November 20, 2026

Tempus AI (TEM): Growth Momentum vs. Profitability Risk

Tempus AI is scaling quickly in diagnostics and data licensing, with improving margins and a growing multimodal data asset. But losses, negative free cash flow, and leverage keep the stock in Hold territory.

Research ReportTEMHealthcareHealth Information ServicesAI
By TickerSpark·November 20, 2026·17 min read

§ Product

  • How It Works
  • Custom Reports
  • AI Analyst
  • Intel Dashboard
  • Spark Charts
  • Trade Tracker
  • My Portfolio
  • Plans

§ Research

  • Main Feed
  • Community
  • Stock Reports
  • Macro Updates
  • Blog

§ Company

  • About Us
  • Contact

§ Fine Print

  • Terms of Service
  • Privacy Policy
  • Full Disclaimer
  • Cookie Policy

Notice: All content and data on TickerSpark is for informational purposes only and does not constitute financial or investment advice. All investments involve risk. Please see our Full Disclaimer for more details.

© 2026 Maxwell Cyberlogic LLC

Not Investment Advice

Made in Delaware, USA

Tempus AI (TEM): Growth Momentum vs. Profitability Risk
C+
Overall
C
Balance Sheet
B-
Income
B
Estimates
C+
Valuation
TickerSpark AI RatingHold
▌Investment Summary
Tempus AI (TEM) looks like a mixed but investable story right now, earning an overall grade of C+ and a Hold. The company is scaling revenue, improving margins, and building a valuable precision-medicine data platform, but profitability remains elusive and leverage is still meaningful. Our fair value estimate of $72 suggests the stock already reflects much of the near-term growth upside.

Thesis

Tempus AI (TEM) has built a credible precision-medicine platform, but the stock still carries the financial profile of an aggressive growth company rather than a mature healthcare technology business. Q3 2026 revenue reached $411.5M, up 23% year over year, while Data & Applications revenue grew 33% and oncology volume increased 32%. Adjusted EBITDA reached $25.6M, compared with $1.5M a year earlier.

The investment case rests on three facts: Tempus is expanding quickly, gross margins are improving, and its diagnostic workflow is generating a large multimodal data asset. The counterweight is equally concrete. The company reported a $56.9M operating loss in Q3, free cash flow remained negative at $5.5M, debt stood at $1.36B at September 30, and the stock traded at $59.61 against an enterprise-value-to-revenue multiple of 8.2x.

For a moderate-risk investor with a medium-term horizon, the right posture is Hold. The business has enough operating momentum to support a higher valuation if execution continues, but the current price already discounts a meaningful portion of the growth story. The central valuation marker in this report is $72 per share.

Company Overview

Tempus AI was incorporated in 2015, listed on Nasdaq on June 14, 2024, and is headquartered in Chicago. The company had approximately 3,800 employees. Its platform connects diagnostic testing, clinical data, software applications, and life-sciences research.

The product portfolio includes genomic testing, pathology, hereditary testing, molecular residual disease monitoring, clinical trial matching, data licensing, and AI applications. Products named in the company presentation include xT, xF, xR, xG, NeXT Dx, ImmunoID NeXT, xM, Lens, Insights, Trials, Next, and Algos.

▌Common Questions

Frequently asked questions

+Is TEM stock a buy right now?
Tempus AI is not a Buy right now; it is a Hold. Revenue growth, margin improvement, and a valuable data platform are encouraging, but the company still posted a $56.9M operating loss and negative free cash flow in Q3.
+What is TEM's fair value?
Tempus AI's fair value is $72. We arrive at that view by weighing the company’s 8.2x enterprise-value-to-revenue multiple, improving gross margins in both Diagnostics and Data & Applications, and the expected 2027 oncology ASP uplift against ongoing losses and negative free cash flow.
+Why does Tempus AI get a Hold rating?
▌The Daily Briefing · Free

A new stock idea, every evening.

One stock worth watching each weekday, plus the analysis behind it. Free, in your inbox.

Creates a free TickerSpark account — newsletter included.

or with email

Daily market recap + weekly preview. One-click unsubscribe in every email.

Tempus describes its strategy as an operating system for precision medicine. Diagnostics generate clinical and molecular information, the data layer organizes that information, and applications turn it into tools for physicians and biopharmaceutical customers. That structure gives TEM more revenue paths than a single-assay laboratory, although it also creates more execution and integration requirements.

Business Segment Deep Dive

Diagnostics generated $303.5M of Q3 2026 revenue, up 20% year over year. Oncology revenue reached $173M and grew 28%, supported by oncology testing volume of approximately 101,500, up 32% from approximately 77,000 in Q3 2025. Hereditary cancer testing generated $111M.

Diagnostics gross margin improved to 62.4% from 61.0% a year earlier. The segment remains the larger operating engine, but reimbursement and test economics matter. Management said the proposed 2027 pricing environment has limited impact on hereditary cancer rates, while oncology pricing changes are expected to provide an $80M ASP uplift in 2027.

Data & Applications produced $108.1M of Q3 revenue, up 33% year over year. Insights, the data licensing business, grew 29%. Segment gross margin reached 71.5%, up from 68.5% in Q3 2025. Management also reported more than $550M of data licensing bookings year to date, with the BMS and Pathos collaborations representing $193M of contracted value over approximately five years.

Get AI research on any stock

Instant reports, daily intelligence, and an AI analyst in your pocket.

Get Started →

Flagship Product Analysis

The flagship asset is the Tempus platform rather than one isolated test. It links clinical workflows with laboratory diagnostics, multimodal data, and applications. That integration is visible in the oncology business, where testing volume creates both direct diagnostic revenue and additional information for data products.

The xT tumor-only assay received FDA approval, and the Q3 presentation states that the DNA solid-tumor portfolio can migrate from an LDT ASP of approximately $2,900 to an xT CDx ASP of $4,500 beginning January 1, 2027. Management also described a path for xF reimbursement or clearance that would add approximately $550 to ASP.

Molecular residual disease is the most visible product expansion. MRD volume reached 9,000 tests in Q3, compared with 6,500 in Q2 and 4,700 in Q4 2025. The presentation reported 300% year-over-year growth with roughly 15% of the salesforce selling the product. The planned Personalis transaction is designed to add the NEXT assay to Tempus' commercial platform.

The product opportunity is substantial, but management also said Personalis currently loses money on individual tests. That fact makes reimbursement progress central to the timing of commercial expansion.

Innovation & Competitive Advantage

Tempus reported more than 600 petabytes of multimodal data and more than 50 petabytes of additions during Q3. The platform connects with approximately 8,000 providers, while the company employs roughly 700 software engineers. These figures support management's claim that the business has accumulated a substantial data and workflow asset.

The advantage is cumulative. More diagnostic interactions create more clinical, molecular, and imaging data. That data supports Lens, Insights, clinical trial matching, and algorithmic diagnostics. Customers can also build analytics and models inside Tempus' environment using dedicated GPU clusters, which gives the data business a recurring software component rather than a simple file-download model.

The strategic collaborations provide external validation. Bristol Myers Squibb agreed to license oncology data and models for up to $138M over five years, while Pathos agreed to pay $55M over five years for work that includes Alzheimer's disease datasets and models. Collaborations with AstraZeneca, Merck, GlaxoSmithKline, Moderna, and BioNTech extend that validation across major pharmaceutical customers.

Operations & Supply Chain

Tempus' operational system combines laboratory processing, software development, provider connectivity, sales coverage, and data governance. The 8,000-provider network and 3,800-person workforce give the company a sizeable distribution base. The Q3 presentation also described long-term GPU deployments, including customers signing up for three years of 32 or 64 GPUs.

Acquisitions have expanded the operating footprint. Tempus completed its $692.3M acquisition of Ambry in February 2025. The 2025 10-K states that Ambry and Paige were excluded from management's internal-control assessment because they were acquired during 2025; together, the businesses represented approximately 11% of assets and 29% of revenue in the related financial statement amounts.

The proposed Personalis acquisition adds another integration task. Regulatory review was cleared, and a shareholder meeting was scheduled for November 30, 2026. Management has said the deal's commercial ramp depends more on reimbursement and per-test economics than on closing alone. That is a sensible operating distinction, because adding sales capacity before gross profit is positive would increase pressure on cash generation.

Market Analysis

Tempus operates in the intersection of precision diagnostics, life-sciences software, clinical data, and AI. Mordor Intelligence estimates the global life-science tools market at $164.47B in 2026, with a projected 6.93% compound annual growth rate through 2031. Its services segment is projected to grow at 11.35%, faster than the overall market.

The technology mix also favors TEM's positioning. Mordor estimates 16.9% growth for next-generation sequencing, while MarketsandMarkets estimates 11.4% growth for life-science analytics through 2030. These figures place Tempus in faster-growing portions of the market, although company performance still depends on reimbursement, test adoption, and biopharma spending.

The market is moving toward integrated clinical services. Deloitte described diagnostics as shifting from laboratory essentials toward clinical services and reported $42B of diagnostics deal value and volume in 2024, driven by spatial multi-omics, AI clinical bioinformatics, and scalable molecular diagnostics. Tempus' combination of laboratory services and software fits that direction.

Like what you're reading?

Get full access to AI-powered research reports, market analysis, and portfolio tools.

Get Started →

Customer Profile

Tempus serves several distinct customer groups. Physicians and academic medical centers use diagnostic tests and clinical applications. Community providers use the platform for testing and treatment support. Pharmaceutical and biotechnology companies use Lens, Insights, data licensing, clinical trial matching, and model-development services.

The customer base has different buying cycles. Diagnostic demand is tied to patient volume, physician adoption, reimbursement, and clinical guidelines. Data and Applications demand is tied to research budgets, drug-development programs, and multi-year contracts. The $550M-plus of year-to-date licensing bookings and the BMS and Pathos agreements show that large biopharma customers are committing to longer-duration relationships.

The hereditary testing opportunity remains underpenetrated according to management. Current guidelines and reimbursement cover about 70 million U.S. lives, while the company said it runs approximately 2 million tests annually. That comparison supports a sizable addressable opportunity, though it does not remove the need for reimbursement and physician adoption.

Competitive Landscape

Tempus faces established competitors in every major category. The 2025 10-K names Foundation Medicine, Caris Life Sciences, Guardant Health, Natera, NeoGenomics, ResolutionBio, Quest Diagnostics, and Labcorp across precision oncology and laboratory services.

The MRD market includes Natera, Guardant Health, Exact Sciences, Personalis, Foundation Medicine, Caris, Myriad Genetics, and Delfi Diagnostics. Hereditary testing competitors include GeneDx, Variantyx, and Baylor Genetics. In data and clinical-trial services, Tempus competes with Flatiron Health, IQVIA, ConcertAI, and large contract research organizations.

Management says Tempus is number one or number two in solid tumor profiling, liquid profiling, hereditary cancer profiling, and eventually MRD. The more durable part of that argument is the platform structure: competitors with strong individual assays do not necessarily offer the same combination of diagnostics, clinical workflow, multimodal data, and life-sciences applications. The market will still test whether that breadth produces superior returns.

Macro & Geopolitical Landscape

The strongest external support comes from AI adoption and life-sciences productivity spending. Deloitte reported that 78% of biopharma and medtech leaders expect AI to play a central role in major change in 2026, while 14% reported full implementation of AI tools in daily workflows and 40% were working toward it.

The main macro risk is customer budget sensitivity. Tempus' life-sciences customers include biotech companies whose research spending can respond to funding conditions. The company's 10-Q also identifies tariffs and restrictive trade policies as factors that can affect demand for data and applications.

Regulation is another direct variable. Diagnostic reimbursement, FDA review, CMS processes, data privacy, and cybersecurity all affect the economics of the platform. The xT CDx pricing change is a positive regulatory event, while the economics of MRD remain linked to reimbursement progress. TEM's beta of 3.6 adds a market-risk layer to those business-specific variables.

Balance Sheet Health

▌Premium Members Only

Debt stood at $1.36B at September 30, while free cash flow was still negative at $5.5M, leaving Tempus with a balance sheet that can support growth but not much margin for error.

Unlock the full analysis

Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.

Get Full Access →

Income Statement Strength

▌Premium Members Only

Q3 revenue rose 23% to $411.5M and adjusted EBITDA improved to $25.6M, but a $56.9M operating loss shows the business is still far from durable profitability.

Unlock the full analysis

Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.

Get Full Access →

Estimates Outlook

▌Premium Members Only

Management pointed to an $80M ASP uplift in 2027 from oncology pricing changes, while xT and xF reimbursement could further lift diagnostics economics if execution holds.

Unlock the full analysis

Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.

Get Full Access →

Valuation Assessment

▌Premium Members Only

At $59.61 per share and 8.2x enterprise value to revenue, Tempus is not cheap for a company with negative free cash flow, even if growth remains strong.

Unlock the full analysis

Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.

Get Full Access →

Target Prices & Recommendation

▌Premium Members Only

The report’s central valuation marker is $72 per share, which sits above the current price but still leaves the stock in Hold range rather than outright buy territory.

Unlock the full analysis

Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.

Get Full Access →

Closing

Tempus AI has crossed an important operating threshold. Q3 2026 delivered $411.5M of revenue, 64.8% gross margin, $25.6M of adjusted EBITDA, and positive operating cash flow. The company also raised its 2026 revenue outlook to approximately $1.6B and expanded its data relationships with major pharmaceutical companies.

The next stage requires conversion. The data moat must produce recurring profits, MRD must move toward positive per-test economics, and acquisitions must expand the platform without extending the cash burn. Analyst estimates provide a path to positive EPS in 2028, but the current financial statements still show a company investing heavily ahead of that outcome.

At $59.61, TEM is too strategically interesting to dismiss and too financially unfinished to chase aggressively. A Hold rating with a $72 fair value estimate fits the evidence: strong growth and improving margins on one side, leverage, volatility, and incomplete cash conversion on the other.

Tempus AI gets a Hold because the growth story is real, but the stock already prices in a meaningful amount of it. The company is still burning cash, carries $1.36B of debt, and needs continued execution before the valuation looks compelling enough for a stronger rating.
+What are the biggest risks for TEM stock?
The biggest risks are continued operating losses, negative free cash flow, and execution risk around reimbursement and product rollout. Management also noted that the planned Personalis transaction involves a business that currently loses money on individual tests, which makes commercialization timing important.
+What is driving Tempus AI's growth?
Growth is being driven by oncology testing, data licensing, and expanding molecular residual disease volume. In Q3, Diagnostics revenue rose to $303.5M, Data & Applications reached $108.1M, and MRD volume climbed to 9,000 tests from 6,500 in Q2.
▌For Active Investors

Want Reports Like This on Any Stock?

Get AI-powered research reports, daily market intelligence, and a personal analyst in your pocket.

Get Full Access →

Not ready to subscribe? ·

▌For Active Investors

Stock research for every investor

  • Reports on any stock
  • Daily market intelligence
  • AI analyst in your pocket
  • Portfolio analysis tools
Get Full Access →

Cancel anytime

▌The Daily Briefing · Free

A new stock idea, every evening.

One stock worth watching each weekday, free in your inbox.

Creates a free TickerSpark account — newsletter included.

or with email

Daily market recap + weekly preview. One-click unsubscribe in every email.

▌More on TEM

More to read

All articles
Tempus AI, Inc. (TEM) climbs 12% on Q3 beat
TEM

Tempus AI, Inc. (TEM) climbs 12% on Q3 beat

Tempus AI, Inc. (TEM) climbs after posting a strong Q3 revenue beat, swinging to adjusted EPS profit, and lifting 2026 revenue guidance. The rally reflects improved operating leverage, stronger growth across its core businesses, and renewed investor confidence in the company’s outlook.

Nov 2·5 min
Tempus AI (TEM): Growth Is Real, but Valuation Is Rich
TEM

Tempus AI (TEM): Growth Is Real, but Valuation Is Rich

Tempus AI is scaling quickly across diagnostics and data licensing, with Q2 revenue up 22% and management lifting 2026 guidance. The stock still looks like a Hold as execution and cash generation need to catch up with a premium valuation.

Oct 5·18 min
Tempus AI, Inc. (TEM) rises 7% on AI momentum
TEM

Tempus AI, Inc. (TEM) rises 7% on AI momentum

Tempus AI, Inc. (TEM) rises after a new Recursion Pharmaceuticals partnership extension and RNA model agreement fueled renewed interest in its healthcare AI platform. Strong volume, recent FDA clearance, and ARPA-H funding added to the rally, though the stock now trades above several analyst targets.

Sep 24·5 min